Alector Therapeutics announced that its Phase 2 trial for an experimental Alzheimer’s antibody, AL002, has failed. The drug was designed to activate microglia, neuronal immune cells, in an attempt to slow the progression of the neurodegenerative disease. However, in the 381-person trial, patients who received AL002 did not show slower decline compared to those on a placebo. The trial also did not demonstrate any effects on secondary measures of cognition and function, or on biomarkers associated with Alzheimer’s, such as amyloid levels. This setback is disappointing for Alector Therapeutics and the field of Alzheimer’s research.
Source link
Alector Therapeutics’ novel Alzheimer’s strategy fails in Phase 2
